Additionally, a study regarding the long-term outcomes of BRAF/MEK in treatment in melanoma patients determined more than 75% of patients who experienced progression-free survival of 4 years from BRAF/MEK inhibitors continued to exhibit lasting and effective anti-tumor responses even after an average follow-up period of nearly 8 years, underscoring the frequent positive outcomes seen in patients who derive prolonged benefit from BRAF/MEK inhibitors [65]. This evidence concerns the gene MAP2K7 and neoplasm.